Representative Bruce Westerman (R-Arkansas) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.
Representative Bruce Westerman also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
- Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
- Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
- Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
- Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
- Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
- Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
- Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
- Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
- Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.
Pfizer Price Performance
Shares of NYSE:PFE opened at $22.86 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a 50-day simple moving average of $23.89 and a 200 day simple moving average of $25.46. The company has a market cap of $129.97 billion, a PE ratio of 16.21, a P/E/G ratio of 0.64 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.52%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.
Get Our Latest Research Report on PFE
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC grew its stake in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after buying an additional 2,923,537 shares during the last quarter. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at $2,328,986,000. Finally, Massachusetts Financial Services Co. MA grew its stake in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
About Representative Westerman
Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.
Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election.
Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
